Introduction to Genetic Modifiers in SCA3

Spinocerebellar ataxia type 3 (SCA3), or Machado-Joseph disease, is the most common hereditary ataxia worldwide. While the primary cause is a CAG repeat expansion in the ATXN3 gene, the age at onset varies significantly among patients. Recent clinical evidence highlights the ATXN2 9bp duplication as a critical genetic modifier in this condition. Specifically, researchers have clarified that this variant influences the disease course when present alongside intermediate-length ATXN2 alleles. Understanding these modifiers is essential for clinicians to provide more accurate prognostic counseling to families affected by neurodegenerative disorders.

Clinical Significance of the ATXN2 9bp Duplication

However, recent debates emerged regarding whether this duplication is protective or pathogenic. Earlier studies suggested a potential protective effect, but new data refutes this claim. Specifically, the ATXN2 9bp duplication does not act in isolation. Its modulatory effect on the age of onset becomes clinically significant when combined with an allele containing 29 CAG repeats. This "double hit" genetic profile likely alters the cellular environment, thereby accelerating or modifying the neurodegenerative process. Furthermore, low frequency in the general population does not negate its biological impact. Rare variants often serve as pivotal modifiers in complex genetic landscapes.

Protein-Level Evidence and Pathogenesis

Moreover, the relevance of this duplication extends beyond simple DNA sequence changes. Convergent evidence from DNA, RNA, and protein studies confirms that the duplication impacts the ATXN2 protein itself. Notably, translation can initiate at multiple sites, such as ATG1 and ATG2, which results in a stable 140-145 kDa protein. Consequently, the ATXN2 9bp duplication is biologically active at the protein level. This finding counters previous assertions that the duplication was only relevant at the DNA level. For neurologists, this underscores the complexity of protein aggregation and stability in spinocerebellar ataxias.

Conclusion and Future Directions

Identifying modifiers like the ATXN2 9bp duplication allows for a deeper understanding of the broader network governing SCA3 pathogenesis. Additionally, these findings emphasize that genetic screening should consider rare variants beyond the primary expansion. Consequently, future diagnostic panels may need to include these specific ATXN2 variants to improve risk stratification. For now, clinicians should remain aware that the interaction between multiple genetic loci often determines the phenotypic variability seen in practice.

Frequently Asked Questions

Is the ATXN2 9bp duplication alone enough to cause ataxia?

No, the duplication is not the primary cause of SCA3. It acts as a genetic modifier that influences the age at onset and disease severity in individuals who already carry the ATXN3 expansion.

Does the duplication have a protective effect against neurodegeneration?

Current evidence does not support a protective effect. Recent studies indicate that previous non-significant results were misinterpreted and that the duplication likely plays a contributory role in disease modification.

Why is protein-level evidence important for this genetic variant?

Protein-level evidence shows that the duplication translates into a functional protein product. This confirms that the variant has a direct biological impact on cellular processes rather than just being a benign change in the DNA sequence.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. It is not intended to be a substitute for professional clinical judgment, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Laffita-Mesa JM et al. The ATXN2 9 bp duplication in SCA3: clarifying evidence and correcting misinterpretations. Acta Neuropathol Commun. 2026 May 01. doi: 10.1186/s40478-026-02305-y. PMID: 42067958.

Lauerer M et al. Influence of ATXN2 intermediate CAG repeats, 9bp duplication and alternative splicing on SCA3 pathogenesis. Acta Neuropathol Commun. 2025;13:157. doi: 10.1186/s40478-025-02074-0.

Laffita-Mesa JM et al. A Novel Duplication in ATXN2 as Modifier for Spinocerebellar Ataxia 3 (SCA3) and C9ORF72-ALS. Movement Disorders. 2020 Oct 15. doi: 10.1002/mds.28334.